US20050147618A1 - Clotting factor-Fc chimeric proteins to treat hemophilia - Google Patents

Clotting factor-Fc chimeric proteins to treat hemophilia Download PDF

Info

Publication number
US20050147618A1
US20050147618A1 US10/841,819 US84181904A US2005147618A1 US 20050147618 A1 US20050147618 A1 US 20050147618A1 US 84181904 A US84181904 A US 84181904A US 2005147618 A1 US2005147618 A1 US 2005147618A1
Authority
US
United States
Prior art keywords
factor
chimeric protein
clotting
constant region
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/841,819
Other languages
English (en)
Inventor
Daniel Rivera
Robert Peters
Alan Bitonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioverativ Therapeutics Inc
Original Assignee
Syntonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33452235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050147618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntonix Pharmaceuticals Inc filed Critical Syntonix Pharmaceuticals Inc
Priority to US10/841,819 priority Critical patent/US20050147618A1/en
Publication of US20050147618A1 publication Critical patent/US20050147618A1/en
Assigned to SYNTONIX PHARMACEUTICALS, INC. reassignment SYNTONIX PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RIVERA, DANIEL S., BITONTI, ALAN J., PETERS, ROBERT T.
Assigned to BIOGEN IDEC INC. reassignment BIOGEN IDEC INC. SECURITY AGREEMENT Assignors: SYNTONIX PHARMACEUTICALS, INC.
Assigned to SYNTONIX PHARMACEUTICALS, INC. reassignment SYNTONIX PHARMACEUTICALS, INC. RELEASE & REASSIGNMENT Assignors: BIOGEN IDEC INC.
Priority to US12/949,564 priority patent/US8449884B2/en
Priority to US13/792,889 priority patent/US8815250B2/en
Assigned to BIOGEN IDEC HEMOPHILIA INC. reassignment BIOGEN IDEC HEMOPHILIA INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SYNTONIX PHARMACEUTICALS, INC.
Priority to US14/334,396 priority patent/US20150044207A1/en
Assigned to BIOVERATIV THERAPEUTICS INC. reassignment BIOVERATIV THERAPEUTICS INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BIOGEN HEMOPHILIA INC.
Priority to US15/866,203 priority patent/US20180237762A1/en
Priority to US17/239,208 priority patent/US20210348150A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
US10/841,819 2003-05-06 2004-05-06 Clotting factor-Fc chimeric proteins to treat hemophilia Abandoned US20050147618A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/841,819 US20050147618A1 (en) 2003-05-06 2004-05-06 Clotting factor-Fc chimeric proteins to treat hemophilia
US12/949,564 US8449884B2 (en) 2003-05-06 2010-11-18 Clotting factor-fc chimeric proteins to treat hemophilia
US13/792,889 US8815250B2 (en) 2003-05-06 2013-03-11 Clotting factor-Fc chimeric proteins to treat hemophilia
US14/334,396 US20150044207A1 (en) 2003-05-06 2014-07-17 Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
US15/866,203 US20180237762A1 (en) 2003-05-06 2018-01-09 Clotting factor-fc chimeric proteins to treat hemophilia
US17/239,208 US20210348150A1 (en) 2003-05-06 2021-04-23 Clotting factor-fc chimeric proteins to treat hemophilia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46883703P 2003-05-06 2003-05-06
US10/841,819 US20050147618A1 (en) 2003-05-06 2004-05-06 Clotting factor-Fc chimeric proteins to treat hemophilia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/949,564 Division US8449884B2 (en) 2003-05-06 2010-11-18 Clotting factor-fc chimeric proteins to treat hemophilia

Publications (1)

Publication Number Publication Date
US20050147618A1 true US20050147618A1 (en) 2005-07-07

Family

ID=33452235

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/841,819 Abandoned US20050147618A1 (en) 2003-05-06 2004-05-06 Clotting factor-Fc chimeric proteins to treat hemophilia
US12/949,564 Expired - Lifetime US8449884B2 (en) 2003-05-06 2010-11-18 Clotting factor-fc chimeric proteins to treat hemophilia
US13/792,889 Expired - Lifetime US8815250B2 (en) 2003-05-06 2013-03-11 Clotting factor-Fc chimeric proteins to treat hemophilia
US14/334,396 Abandoned US20150044207A1 (en) 2003-05-06 2014-07-17 Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
US15/866,203 Abandoned US20180237762A1 (en) 2003-05-06 2018-01-09 Clotting factor-fc chimeric proteins to treat hemophilia
US17/239,208 Abandoned US20210348150A1 (en) 2003-05-06 2021-04-23 Clotting factor-fc chimeric proteins to treat hemophilia

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/949,564 Expired - Lifetime US8449884B2 (en) 2003-05-06 2010-11-18 Clotting factor-fc chimeric proteins to treat hemophilia
US13/792,889 Expired - Lifetime US8815250B2 (en) 2003-05-06 2013-03-11 Clotting factor-Fc chimeric proteins to treat hemophilia
US14/334,396 Abandoned US20150044207A1 (en) 2003-05-06 2014-07-17 Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
US15/866,203 Abandoned US20180237762A1 (en) 2003-05-06 2018-01-09 Clotting factor-fc chimeric proteins to treat hemophilia
US17/239,208 Abandoned US20210348150A1 (en) 2003-05-06 2021-04-23 Clotting factor-fc chimeric proteins to treat hemophilia

Country Status (19)

Country Link
US (6) US20050147618A1 (fr)
EP (5) EP2298347B1 (fr)
AT (2) ATE440619T1 (fr)
AU (2) AU2004239244C1 (fr)
BE (1) BE2016C058I2 (fr)
CA (1) CA2522859C (fr)
CY (4) CY1109640T1 (fr)
DE (2) DE602004022800D1 (fr)
DK (3) DK2298347T3 (fr)
ES (3) ES2333598T5 (fr)
FR (1) FR16C0041I2 (fr)
HK (2) HK1153947A1 (fr)
HU (2) HUE026384T2 (fr)
LU (1) LU93265I2 (fr)
NL (1) NL300835I2 (fr)
PL (3) PL2077121T3 (fr)
PT (3) PT2077121E (fr)
SI (3) SI1624891T2 (fr)
WO (1) WO2004101740A2 (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261229A1 (en) * 1999-07-21 2005-11-24 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20070172928A1 (en) * 2003-05-06 2007-07-26 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2010111414A1 (fr) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Variants du facteur viii et procédés d'utilisation associés
US20110182896A1 (en) * 2003-05-06 2011-07-28 Syntonix Pharmaceuticals, Inc. CLOTTING FACTOR-Fc CHIMERIC PROTEINS TO TREAT HEMOPHILIA
WO2011060242A3 (fr) * 2009-11-13 2011-10-13 Talecris Biotherapeutics, Inc. Préparations contenant le facteur de von willebrand (vwf) et procédés, coffrets et utilisations s'y rapportant
WO2012061654A1 (fr) 2010-11-03 2012-05-10 Catalyst Biosciences, Inc. Polypeptides de facteur ix modifiés et leurs applications
US20130108629A1 (en) * 2009-12-06 2013-05-02 Biogen Idec Hemophilia Inc. Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
CN103180439A (zh) * 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
US20130296534A1 (en) * 2010-10-20 2013-11-07 Sk Chemicals Co., Ltd. Fusion protein having factor ix activity
US20140370035A1 (en) * 2012-01-12 2014-12-18 Biogen Idec Ma Inc. Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US8980610B2 (en) 2008-11-20 2015-03-17 Biogen Idec Ma Inc. Arginine inactivation of viruses
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9062115B2 (en) 2010-09-22 2015-06-23 Novo Nordisk A/S Therapeutic factor VIII antibodies
US20150184142A1 (en) * 2012-06-08 2015-07-02 Biogen Idec Ma Inc. Procoagulant compounds
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US20150315262A1 (en) * 2012-12-10 2015-11-05 Vib Vzw Novel interleukin-33 inhibitors
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US20150353911A1 (en) * 2012-06-08 2015-12-10 Biogen Idec Ma Inc. Chimeric clotting factors
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP1984503B2 (fr) † 2006-02-06 2018-08-15 CSL Behring GmbH Facteur de coagulation viia modifie a demi-vie prolongee
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
US10421798B2 (en) 2012-02-15 2019-09-24 Bioverativ Therapeutics Inc. Factor VIII compositions and methods of making and using same
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US11081211B2 (en) 2013-06-20 2021-08-03 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
WO2021154414A2 (fr) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés
US11135275B2 (en) * 2011-03-02 2021-10-05 Novo Nordisk Healthcare Ag Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets
US11192936B2 (en) 2014-01-10 2021-12-07 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US11642398B2 (en) 2013-03-15 2023-05-09 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1771066A2 (fr) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1
WO2006050247A2 (fr) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
AU2006206187B2 (en) * 2005-01-24 2011-03-10 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
EP2386571B1 (fr) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
MX2007013156A (es) 2005-04-28 2008-01-18 Novo Nordisk Healthcare Ag Envase cerrado que comprende un polipeptido del factor vii activado, procesos para la preparacion del mismo y kit y metodo para el uso del kit.
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007112005A2 (fr) 2006-03-24 2007-10-04 Syntonix Pharmaceuticals, Inc. Protéine pc5 utilisée comme enzyme de traitement du propeptide du facteur ix
CN104593348A (zh) 2006-05-24 2015-05-06 诺沃—诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
JP5800458B2 (ja) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質
EP1867660A1 (fr) 2006-06-14 2007-12-19 CSL Behring GmbH Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
WO2008057683A2 (fr) 2006-10-03 2008-05-15 Novo Nordisk A/S Méthodes de purification de conjugués de polypeptides
EP1935430A1 (fr) * 2006-12-22 2008-06-25 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2526962B1 (fr) 2007-02-12 2019-08-14 CSL Behring GmbH Application thérapeutique d'inhibiteurs de la sérine protéase de type Kazal
BRPI0809670A8 (pt) 2007-04-03 2018-12-18 Biogenerix Ag métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
CN103497246B (zh) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 缀合的因子viii分子
ES2654336T3 (es) 2008-06-24 2018-02-13 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
EP2371857A1 (fr) 2010-04-01 2011-10-05 CSL Behring GmbH Inhibiteurs de facteur XII pour traiter la maladie de poumon interstitiel
EP3508573A1 (fr) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systèmes de traitement de facteur viii et procédés associés
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
EP2497489A1 (fr) 2011-03-09 2012-09-12 CSL Behring GmbH Inhibiteur du facteur XII pour le traitement de la pénombre ischémique cérébrale et l'ischémie d'autres organes
EP2683397B1 (fr) 2011-03-09 2017-08-09 CSL Behring GmbH Inhibiteurs du facteur xii destinés à être administrés avec des procédures médicales comprenant le contact avec des surfaces artificielles
MY180714A (en) 2011-07-08 2020-12-07 Bioverativ Therapeutics Inc Factor viii chimeric and hybrid polypeptides, and methods of use thereof
CA2841185C (fr) 2011-07-22 2021-05-25 Csl Behring Gmbh Anticorps monoclonaux inhibiteurs anti-facteur xii/xiia et leurs utilisations
EP2768522B1 (fr) 2011-10-18 2016-07-27 CSL Behring GmbH Utilisation de glycosaminoglycanes sulfatés pour améliorer la biodisponibilité des facteurs de coagulation sanguine
KR20140084208A (ko) 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
EP2623110A1 (fr) 2012-01-31 2013-08-07 CSL Behring GmbH Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
EP3970738A1 (fr) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Essai de surveillance de facteur sanguin et utilisations de celui-ci
TWI810729B (zh) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (fr) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Procédés d'utilisation du polypeptide fviii
JP6636334B2 (ja) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 遠隔虚血再灌流傷害の治療および予防
HUE047933T2 (hu) 2013-03-15 2020-05-28 Bioverativ Therapeutics Inc Faktor VIII polipeptid készítmények
EP2796145B1 (fr) 2013-04-22 2017-11-01 CSL Ltd. Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure
ES2897746T3 (es) 2013-06-28 2022-03-02 Csl Behring Gmbh Terapia combinada con un inhibidor del Factor XII y un inhibidor de C1
EP3903599A1 (fr) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
EP4332839A2 (fr) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Outils pharmacocinétiques de population et leurs utilisations
MX2016012447A (es) 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.
PL3157548T3 (pl) 2014-06-18 2022-01-17 Csl Behring Gmbh Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
KR20170026580A (ko) 2014-07-02 2017-03-08 씨에스엘 리미티드 변형된 폰 빌레브란트 인자
CN104292341B (zh) * 2014-10-11 2018-08-10 上海兴迪金生物技术有限公司 一种凝血八因子融合蛋白及其制备方法和用途
WO2016100788A1 (fr) 2014-12-19 2016-06-23 Alkermes, Inc. Protéines de fusion fc à chaîne unique
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
AU2016266627A1 (en) 2015-05-22 2018-01-18 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
RU2017145002A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Способы получения модифицированного фактора фон виллебранда
EP3184149A1 (fr) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotéine v soluble pour le traitement de maladies thrombotiques
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
ES2881701T3 (es) 2016-01-07 2021-11-30 CSL Behring Lengnau AG Factor de von Willebrand mutado
WO2017173494A1 (fr) 2016-04-06 2017-10-12 Csl Limited Méthode de traitement de l'athérosclérose
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
CA3044838A1 (fr) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Procedes d'induction de tolerance immunitaire a des facteurs de coagulation
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
AU2018235945A1 (en) 2017-03-14 2019-10-17 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates
KR20200018690A (ko) 2017-06-22 2020-02-19 체에스엘 베링 렝나우 아게 절단된 vwf에 의한 fviii 면역원성의 조절
CA3077380A1 (fr) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Procedes, compositions et elements implantables comprenant des cellules actives
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
WO2019195056A1 (fr) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Procédés, compositions et éléments implantables comprenant des cellules souches
EP3773517A1 (fr) 2018-04-04 2021-02-17 Sigilon Therapeutics, Inc. Particules implantables et procédés associés
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
JP2022533365A (ja) 2019-05-17 2022-07-22 ウニベルシテート チューリッヒ 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン
CN114072420A (zh) 2019-07-04 2022-02-18 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
WO2021094344A1 (fr) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides pour induire une tolérance au facteur viii
JP2023514152A (ja) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１０およびその使用
KR20230097094A (ko) 2020-10-29 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 질환의 치료를 위한 융합 단백질
EP4247416A1 (fr) 2020-11-20 2023-09-27 CSL Behring GmbH Méthodes de traitement d?un rejet à médiation par anticorps
AU2022214388A1 (en) 2021-02-01 2023-07-27 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
CA3217518A1 (fr) 2021-05-07 2022-11-10 Rebecca Butcher Systeme d'expression pour la production d'une chaine beta de l'haptoglobine (hp) recombinante
WO2024047219A1 (fr) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobine destinée à être utilisée dans le traitement ou la prévention d'une réponse érectile exagérée ou d'un dysfonctionnement érectile
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2024081310A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Citations (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4695623A (en) * 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US4784950A (en) * 1985-04-17 1988-11-15 Zymogenetics, Inc. Expression of factor VII activity in mammalian cells
US4831119A (en) * 1984-11-05 1989-05-16 Ole Nordfang Preparation for the treatment of hemophilia A inhibitor patients and a process for producing such a preparation
US5077204A (en) * 1984-06-21 1991-12-31 Chiron Corporation Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
US5093246A (en) * 1986-12-03 1992-03-03 University Patents, Inc. Rna ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5162220A (en) * 1988-02-03 1992-11-10 Suntory Limited Kex2 endoprotease without a c-terminal hydrophobic region
US5175096A (en) * 1989-05-11 1992-12-29 Alfa-Laval Agri International Aktiebolag Dna encoding a fibronectin binding protein as well as its preparation
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5189015A (en) * 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
US5234830A (en) * 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5428130A (en) * 1989-02-23 1995-06-27 Genentech, Inc. Hybrid immunoglobulins
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5480981A (en) * 1992-05-26 1996-01-02 Immunex Corporation CD30 ligand
US5579277A (en) * 1995-05-01 1996-11-26 Apple Computer, Inc. System and method for interleaving memory banks
US5585089A (en) * 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5591573A (en) * 1995-04-10 1997-01-07 Alpha Therapeutic Corporation Method and system for testing blood samples
US5605689A (en) * 1991-05-31 1997-02-25 Genentech, Inc. Treatment of HIV-associated immune thrombocytopenic purpura
US5624821A (en) * 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5808029A (en) * 1989-09-12 1998-09-15 Hoffmann-La Roche Inc. DNA encoding a human TNF binding protein
US5807706A (en) * 1995-03-01 1998-09-15 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5885821A (en) * 1996-03-04 1999-03-23 Suntory Limited Process for production of secretory Kex2 derivatives
US5910573A (en) * 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
US6013263A (en) * 1993-06-07 2000-01-11 Trimeris, Inc. Measles virus peptides with antifusogenic and antiviral activities
US6015881A (en) * 1998-03-23 2000-01-18 Trimeris, Inc. Methods and compositions for peptide synthesis
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6060613A (en) * 1997-02-05 2000-05-09 Ajinomoto Co., Inc. Process for producing N-long-chain acyl acidic amino acids or salts thereof
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6093799A (en) * 1998-03-16 2000-07-25 Pharmacopeia, Inc. Universal linker for combinatorial synthesis
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6280994B1 (en) * 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6310180B1 (en) * 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
US6323323B1 (en) * 1988-01-22 2001-11-27 Zymogenetics, Inc. Ligand-binding, dimerized polypeptide fusions
US6326468B1 (en) * 1997-06-13 2001-12-04 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6329176B1 (en) * 1998-11-06 2001-12-11 Novo Nordisk A/S Method for the production of factor VII
US20020081664A1 (en) * 1999-05-19 2002-06-27 Kin-Ming Lo Expression and export of interferon-alpha proteins as Fc fusion proteins
US20020106374A1 (en) * 2000-09-15 2002-08-08 Olson William C. Compositions and methods for inhibition of HIV-1 infection
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6475491B1 (en) * 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US20030180287A1 (en) * 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20040077022A1 (en) * 1998-10-23 2004-04-22 Ulrich Feige Modified peptides as therapeutic agents
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
US20050027109A1 (en) * 2003-05-06 2005-02-03 Mezo Adam R. Methods for chemically synthesizing immunoglobulin chimeric proteins
US20050037947A1 (en) * 2003-05-06 2005-02-17 Bitonti Alan J. Inhibition of drug binding to serum albumin
US20050037941A1 (en) * 2001-10-24 2005-02-17 Benchmark Research And Technology, Inc. Contaminant-tolerant foaming additive
US7084109B2 (en) * 1999-07-02 2006-08-01 Genentech, Inc. FVIIa antagonists
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7385032B2 (en) * 1999-12-30 2008-06-10 Apotech Research And Development Ltd. Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4456591A (en) * 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
PT89484B (pt) 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
FR2641468A1 (fr) 1989-01-11 1990-07-13 Merieux Inst Anticorps chimeriques anti-recepteur de l'interleukine-2 humaine, leur preparation et compositions pharmaceutiques les contenant
GB9009106D0 (en) 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
ATE169030T1 (de) * 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
WO1993006848A1 (fr) * 1991-10-03 1993-04-15 The Center For Blood Research IMMUNOADHESINES DE CD36 ET LEUR UTILISATION POUR TUER DE MANIERE SELECTIVE LES ERYTHROCYTES INFECTES PAR $i(PLASMODIUM FALCIPARUM)
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1994005328A1 (fr) 1992-08-28 1994-03-17 The Scripps Research Institute Inhibitions des metastases tumorales par neutralisation de la fonction de la thromboplastine tissulaire
GB2270845B (en) 1992-09-24 1996-07-10 Smiths Ind Med Syst Inc Suction catheter assemblies
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
ES2194973T3 (es) 1995-01-17 2003-12-01 Brigham & Womens Hospital Transporte de inmunogenes transepitelial especifico del receptor.
US6036482A (en) † 1995-02-10 2000-03-14 Tokyo Electron Limited Heat treatment method
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
ATE244579T1 (de) 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
CA2225189C (fr) * 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
AU4090299A (en) 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
DE69911793T2 (de) 1998-07-28 2004-08-12 Micromet Ag Heterominikörper
CA2341029A1 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
JP4749548B2 (ja) 1998-09-30 2011-08-17 ニユー・イングランド・バイオレイブズ・インコーポレイテツド インテイン媒介ペプチド連結
CA2270600A1 (fr) 1999-05-03 2000-11-03 Infectio Recherche Inc. Methode et preparations pour le traitement de maladies, en particulier de celles causees par le virus de l'immunodeficience humaine et leishmania
ATE398633T1 (de) 1999-07-01 2008-07-15 Univ Yale Neovaskulär gerichtete immunkonjugate
IL147270A0 (en) * 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
NZ517184A (en) † 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
IL149202A0 (en) 1999-11-05 2002-11-10 Biogen Inc Hedgehog fusion proteins and uses
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
EP1252192B1 (fr) 2000-02-11 2006-08-16 MERCK PATENT GmbH Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20020090646A1 (en) † 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
CN1318084C (zh) 2000-05-26 2007-05-30 奥索-麦克尼尔药品公司 神经保护肽
CA2412424A1 (fr) 2000-09-01 2002-03-07 Gryphon Therapeutics, Inc. Composes produisant des thioesters stables avec les nucleophiles, procedes de production et d'utilisation
EP1339427A4 (fr) 2000-11-01 2004-09-15 Elusys Therapeutics Inc Procede de production de molecules bispecifiques par transepissage de proteines
AU2002310922A1 (en) 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
WO2004003176A2 (fr) 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
CA2491129A1 (fr) 2002-07-03 2004-01-15 Brigham And Women's Hospital, Inc. Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
EP1523504A2 (fr) * 2002-07-12 2005-04-20 Novo Nordisk A/S Compose de liaison au facteur tissulaire
WO2004108885A2 (fr) 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Proteines chimeres fc avec medicaments anti-vih
DK2298347T3 (en) 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1684790A4 (fr) * 2003-11-18 2008-04-30 Iconic Therapeutics Inc Preparations homogenes de proteines chimeres
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
MY180714A (en) * 2011-07-08 2020-12-07 Bioverativ Therapeutics Inc Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EP3291154A1 (fr) 2015-04-28 2018-03-07 Sato Holdings Kabushiki Kaisha Armoire de stockage

Patent Citations (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4695623A (en) * 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US4897471A (en) * 1982-05-06 1990-01-30 Amgen Consensus human leukocyte interferon
US5189015A (en) * 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
US5077204A (en) * 1984-06-21 1991-12-31 Chiron Corporation Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
US4831119A (en) * 1984-11-05 1989-05-16 Ole Nordfang Preparation for the treatment of hemophilia A inhibitor patients and a process for producing such a preparation
US4784950A (en) * 1985-04-17 1988-11-15 Zymogenetics, Inc. Expression of factor VII activity in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5093246A (en) * 1986-12-03 1992-03-03 University Patents, Inc. Rna ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods
US5624821A (en) * 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5482858A (en) * 1987-05-21 1996-01-09 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US6323323B1 (en) * 1988-01-22 2001-11-27 Zymogenetics, Inc. Ligand-binding, dimerized polypeptide fusions
US5162220A (en) * 1988-02-03 1992-11-10 Suntory Limited Kex2 endoprotease without a c-terminal hydrophobic region
US5234830A (en) * 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
US5585089A (en) * 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5428130A (en) * 1989-02-23 1995-06-27 Genentech, Inc. Hybrid immunoglobulins
US5175096A (en) * 1989-05-11 1992-12-29 Alfa-Laval Agri International Aktiebolag Dna encoding a fibronectin binding protein as well as its preparation
US5808029A (en) * 1989-09-12 1998-09-15 Hoffmann-La Roche Inc. DNA encoding a human TNF binding protein
US5605689A (en) * 1991-05-31 1997-02-25 Genentech, Inc. Treatment of HIV-associated immune thrombocytopenic purpura
US5910573A (en) * 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
US5480981A (en) * 1992-05-26 1996-01-02 Immunex Corporation CD30 ligand
US6060065A (en) * 1993-06-07 2000-05-09 Trimeris, Inc. Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6228983B1 (en) * 1993-06-07 2001-05-08 Trimeris, Inc. Human respiratory syncytial virus peptides with antifusogenic and antiviral activities
US6068973A (en) * 1993-06-07 2000-05-30 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including influenza virus
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6013263A (en) * 1993-06-07 2000-01-11 Trimeris, Inc. Measles virus peptides with antifusogenic and antiviral activities
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6310180B1 (en) * 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5807706A (en) * 1995-03-01 1998-09-15 Genentech, Inc. Method for making heteromultimeric polypeptides
US5591573A (en) * 1995-04-10 1997-01-07 Alpha Therapeutic Corporation Method and system for testing blood samples
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5579277A (en) * 1995-05-01 1996-11-26 Apple Computer, Inc. System and method for interleaving memory banks
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6475491B1 (en) * 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5885821A (en) * 1996-03-04 1999-03-23 Suntory Limited Process for production of secretory Kex2 derivatives
US6060613A (en) * 1997-02-05 2000-05-09 Ajinomoto Co., Inc. Process for producing N-long-chain acyl acidic amino acids or salts thereof
US6326468B1 (en) * 1997-06-13 2001-12-04 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6093799A (en) * 1998-03-16 2000-07-25 Pharmacopeia, Inc. Universal linker for combinatorial synthesis
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6015881A (en) * 1998-03-23 2000-01-18 Trimeris, Inc. Methods and compositions for peptide synthesis
US20040077022A1 (en) * 1998-10-23 2004-04-22 Ulrich Feige Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6329176B1 (en) * 1998-11-06 2001-12-11 Novo Nordisk A/S Method for the production of factor VII
US6280994B1 (en) * 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
US20020081664A1 (en) * 1999-05-19 2002-06-27 Kin-Ming Lo Expression and export of interferon-alpha proteins as Fc fusion proteins
US7084109B2 (en) * 1999-07-02 2006-08-01 Genentech, Inc. FVIIa antagonists
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US7385032B2 (en) * 1999-12-30 2008-06-10 Apotech Research And Development Ltd. Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
US20020106374A1 (en) * 2000-09-15 2002-08-08 Olson William C. Compositions and methods for inhibition of HIV-1 infection
US20050037941A1 (en) * 2001-10-24 2005-02-17 Benchmark Research And Technology, Inc. Contaminant-tolerant foaming additive
US20030180287A1 (en) * 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
US20050037947A1 (en) * 2003-05-06 2005-02-17 Bitonti Alan J. Inhibition of drug binding to serum albumin
US20050027109A1 (en) * 2003-05-06 2005-02-03 Mezo Adam R. Methods for chemically synthesizing immunoglobulin chimeric proteins
US20070172928A1 (en) * 2003-05-06 2007-07-26 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7381408B2 (en) * 2003-05-06 2008-06-03 Syntonix Pharmaceuticals, Inc. Methods for chemically synthesizing immunoglobulin chimeric proteins
US7404956B2 (en) * 2003-05-06 2008-07-29 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20080249288A1 (en) * 2003-05-06 2008-10-09 Syntonix Pharmaceuticals, Inc. Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins

Cited By (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955590B2 (en) 1999-07-21 2011-06-07 Merck Patent Gmbh Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20050261229A1 (en) * 1999-07-21 2005-11-24 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US8043608B2 (en) 1999-07-21 2011-10-25 Merck Patent Gmbh Methods of using Fc-cytokine fusion proteins
US20100068175A1 (en) * 1999-07-21 2010-03-18 Gillies Stephen D Methods of using Fc-Cytokine fusion proteins
US9725496B1 (en) 2003-05-06 2017-08-08 Bioverative Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20070172928A1 (en) * 2003-05-06 2007-07-26 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7862820B2 (en) 2003-05-06 2011-01-04 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US11401322B2 (en) 2003-05-06 2022-08-02 Bioverativ Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20110182919A1 (en) * 2003-05-06 2011-07-28 Peters Robert T Immunoglobulin Chimeric Monomer-Dimer Hybrids
US20110182896A1 (en) * 2003-05-06 2011-07-28 Syntonix Pharmaceuticals, Inc. CLOTTING FACTOR-Fc CHIMERIC PROTEINS TO TREAT HEMOPHILIA
US8932830B2 (en) 2003-05-06 2015-01-13 Biogen Idec Hemophilia, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20080249288A1 (en) * 2003-05-06 2008-10-09 Syntonix Pharmaceuticals, Inc. Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins
US8815250B2 (en) 2003-05-06 2014-08-26 Biogen Idec Hemophilia Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US11168125B2 (en) 2003-05-06 2021-11-09 Bioverativ Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
US9636416B2 (en) 2003-05-06 2017-05-02 Bioverativ Therapeutics Inc. Immunoglobulin chimeric monomer-dimer hybrids
US8449884B2 (en) 2003-05-06 2013-05-28 Syntonix Pharmaceuticals, Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US8329182B2 (en) 2003-05-06 2012-12-11 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7820162B2 (en) 2003-05-06 2010-10-26 Syntonix Pharmaceuticals, Inc. Methods for chemically synthesizing immunoglobulin chimeric proteins
EP2233576B1 (fr) * 2006-02-06 2020-04-08 CSL Behring GmbH Facteur de coagulation VIIa modifié à demi-vie prolongée
EP1984503B2 (fr) † 2006-02-06 2018-08-15 CSL Behring GmbH Facteur de coagulation viia modifie a demi-vie prolongee
US8980610B2 (en) 2008-11-20 2015-03-17 Biogen Idec Ma Inc. Arginine inactivation of viruses
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9879249B2 (en) 2009-02-17 2018-01-30 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
WO2010111414A1 (fr) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Variants du facteur viii et procédés d'utilisation associés
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
US8759293B2 (en) * 2009-11-13 2014-06-24 Grifols Therapeutics Inc. von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
WO2011060242A3 (fr) * 2009-11-13 2011-10-13 Talecris Biotherapeutics, Inc. Préparations contenant le facteur de von willebrand (vwf) et procédés, coffrets et utilisations s'y rapportant
US20120289468A1 (en) * 2009-11-13 2012-11-15 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
CN102648212A (zh) * 2009-11-13 2012-08-22 基立福疗法公司 包含冯维勒布兰德因子(vWF)的制剂及其相关制备方法、试剂盒和用途
AU2010319425B2 (en) * 2009-11-13 2015-07-02 Grifols Therapeutics Inc. Von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
US9050318B2 (en) * 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2016213822B2 (en) * 2009-12-06 2017-08-31 Bioverativ Therapeutics Inc. Factor VIII-Fc Chimeric And Hybrid Polypeptides, And Methods Of Use Thereof
AU2010325787B2 (en) * 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
US9241978B2 (en) 2009-12-06 2016-01-26 Biogen Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
US11266720B2 (en) 2009-12-06 2022-03-08 Bioverativ Therapeutics Inc. Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
US20130108629A1 (en) * 2009-12-06 2013-05-02 Biogen Idec Hemophilia Inc. Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
US10968442B2 (en) 2010-07-09 2021-04-06 Bioverativ Therapeutics Inc. Chimeric clotting factors
US10927362B2 (en) * 2010-07-09 2021-02-23 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
US20130216513A1 (en) * 2010-07-09 2013-08-22 Biogen Idec Hemophilia Inc. Chimeric Clotting Factors
CN103180439A (zh) * 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
US9856468B2 (en) * 2010-07-09 2018-01-02 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
US20130202596A1 (en) * 2010-07-09 2013-08-08 Biogen Idec Hemophilia Inc. Processable Single Chain Molecules and Polypeptides Made Using Same
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9062115B2 (en) 2010-09-22 2015-06-23 Novo Nordisk A/S Therapeutic factor VIII antibodies
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10064959B2 (en) 2010-10-01 2018-09-04 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9701965B2 (en) 2010-10-01 2017-07-11 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US20130296534A1 (en) * 2010-10-20 2013-11-07 Sk Chemicals Co., Ltd. Fusion protein having factor ix activity
US9617328B2 (en) * 2010-10-20 2017-04-11 Sk Chemicals Co., Ltd. Fusion protein having factor IX activity
EP3663399A1 (fr) 2010-11-03 2020-06-10 Catalyst Biosciences, Inc. Polypeptides du facteur ix modifiés et leurs utilisations
US8778870B2 (en) 2010-11-03 2014-07-15 Catalyst Biosciences, Inc. Modified factor IX polypeptides and uses thereof
US10982203B2 (en) 2010-11-03 2021-04-20 Catalyst Biosciences, Inc. Modified factor IX polypeptides and uses thereof
US9328339B2 (en) 2010-11-03 2016-05-03 Catalyst Biosciences, Inc. Modified factor IX polypeptides and uses thereof
WO2012061654A1 (fr) 2010-11-03 2012-05-10 Catalyst Biosciences, Inc. Polypeptides de facteur ix modifiés et leurs applications
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
US10183998B2 (en) 2011-01-14 2019-01-22 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
US11135275B2 (en) * 2011-03-02 2021-10-05 Novo Nordisk Healthcare Ag Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9950068B2 (en) 2011-03-31 2018-04-24 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US11747351B2 (en) 2011-07-25 2023-09-05 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10022425B2 (en) 2011-09-12 2018-07-17 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US20140370035A1 (en) * 2012-01-12 2014-12-18 Biogen Idec Ma Inc. Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
US11286528B2 (en) 2012-01-12 2022-03-29 Bioverativ Therapeutics Inc. Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
US10221455B2 (en) * 2012-01-12 2019-03-05 Bioverativ Therapeutics Inc. Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
US10421798B2 (en) 2012-02-15 2019-09-24 Bioverativ Therapeutics Inc. Factor VIII compositions and methods of making and using same
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9782462B2 (en) 2012-04-02 2017-10-10 Modernatx, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9255129B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10287564B2 (en) * 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
US10202595B2 (en) * 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
US20150184142A1 (en) * 2012-06-08 2015-07-02 Biogen Idec Ma Inc. Procoagulant compounds
US11261437B2 (en) 2012-06-08 2022-03-01 Bioverativ Therapeutics Inc. Procoagulant compounds
US11168316B2 (en) 2012-06-08 2021-11-09 Bioverativ Therapeutics, Inc. Chimeric clotting factors
US20150353911A1 (en) * 2012-06-08 2015-12-10 Biogen Idec Ma Inc. Chimeric clotting factors
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US11091534B2 (en) 2012-07-11 2021-08-17 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10703799B2 (en) * 2012-12-10 2020-07-07 Vib Vzw IL-33R and IL-1RAcP fusion proteins
US20150315262A1 (en) * 2012-12-10 2015-11-05 Vib Vzw Novel interleukin-33 inhibitors
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US11642398B2 (en) 2013-03-15 2023-05-09 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
US11081211B2 (en) 2013-06-20 2021-08-03 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US11749394B2 (en) 2013-06-20 2023-09-05 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US11192936B2 (en) 2014-01-10 2021-12-07 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
US20220275057A1 (en) * 2014-01-10 2022-09-01 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
US11670409B2 (en) 2016-04-15 2023-06-06 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US11788066B2 (en) 2016-04-26 2023-10-17 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US11783931B2 (en) 2017-01-27 2023-10-10 Takeda Pharmaceutical Company Limited Drug monitoring tool
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
WO2021154414A2 (fr) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés

Also Published As

Publication number Publication date
ES2333598T5 (es) 2013-09-04
SI1624891T2 (sl) 2013-09-30
SI2298347T1 (sl) 2016-03-31
CY1109640T1 (el) 2014-08-13
PT1624891E (pt) 2010-01-05
AU2004239244B2 (en) 2010-01-28
AU2004239244C1 (en) 2015-04-23
US8815250B2 (en) 2014-08-26
US20110182896A1 (en) 2011-07-28
CY2016039I1 (el) 2017-03-15
EP1624891B1 (fr) 2009-08-26
HUS1600041I1 (hu) 2016-11-28
EP1624891A4 (fr) 2007-06-06
SI1624891T1 (sl) 2010-01-29
US20130273047A1 (en) 2013-10-17
AU2004239244A1 (en) 2004-11-25
AU2010201711A1 (en) 2010-05-20
ES2361036T3 (es) 2011-06-13
PT2298347E (pt) 2016-01-29
DE602004031390D1 (de) 2011-03-24
EP3552627A1 (fr) 2019-10-16
SI2077121T1 (sl) 2011-07-29
US20150044207A1 (en) 2015-02-12
AU2010201711C1 (en) 2012-11-08
WO2004101740A3 (fr) 2005-10-27
CA2522859C (fr) 2017-10-24
EP3002012A9 (fr) 2016-11-16
DK1624891T4 (da) 2013-07-15
PL2298347T3 (pl) 2016-03-31
CY1117090T1 (el) 2017-03-15
NL300835I2 (fr) 2017-03-16
LU93265I2 (fr) 2016-12-19
CY2016039I2 (el) 2017-03-15
ATE497783T1 (de) 2011-02-15
ES2558102T3 (es) 2016-02-02
DK1624891T3 (da) 2010-01-04
FR16C0041I1 (fr) 2016-09-12
BE2016C058I2 (fr) 2023-08-09
HUE026384T2 (en) 2016-06-28
DK2077121T3 (da) 2011-06-06
US20180237762A1 (en) 2018-08-23
HK1134432A1 (en) 2010-04-30
PL2077121T3 (pl) 2011-07-29
FR16C0041I2 (fr) 2019-07-05
EP2077121B1 (fr) 2011-02-09
PL1624891T3 (pl) 2010-02-26
CY1111725T1 (el) 2015-10-07
PL1624891T5 (pl) 2014-02-28
EP2077121A1 (fr) 2009-07-08
DK2298347T3 (en) 2016-01-11
EP1624891A2 (fr) 2006-02-15
HK1153947A1 (zh) 2012-04-20
PT2077121E (pt) 2011-05-23
CA2522859A1 (fr) 2004-11-25
AU2010201711B2 (en) 2012-04-05
ATE440619T1 (de) 2009-09-15
EP2298347B1 (fr) 2015-09-30
ES2333598T3 (es) 2010-02-24
EP3002012A1 (fr) 2016-04-06
US8449884B2 (en) 2013-05-28
DE602004022800D1 (de) 2009-10-08
EP2298347A1 (fr) 2011-03-23
EP1624891B2 (fr) 2013-04-10
WO2004101740A2 (fr) 2004-11-25
US20210348150A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
US20210348150A1 (en) Clotting factor-fc chimeric proteins to treat hemophilia
US20230023927A1 (en) Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) Immunoglobulin chimeric monomer-dimer hybrids
AU2012203896B2 (en) Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
AU2012200470B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids
AU2016244273A1 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYNTONIX PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIVERA, DANIEL S.;PETERS, ROBERT T.;BITONTI, ALAN J.;REEL/FRAME:018501/0640;SIGNING DATES FROM 20041006 TO 20041108

AS Assignment

Owner name: BIOGEN IDEC INC., MASSACHUSETTS

Free format text: SECURITY AGREEMENT;ASSIGNOR:SYNTONIX PHARMACEUTICALS, INC.;REEL/FRAME:018764/0586

Effective date: 20061221

AS Assignment

Owner name: SYNTONIX PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: RELEASE & REASSIGNMENT;ASSIGNOR:BIOGEN IDEC INC.;REEL/FRAME:018964/0431

Effective date: 20070221

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIOGEN IDEC HEMOPHILIA INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:SYNTONIX PHARMACEUTICALS, INC.;REEL/FRAME:032753/0837

Effective date: 20100519

AS Assignment

Owner name: BIOVERATIV THERAPEUTICS INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:BIOGEN HEMOPHILIA INC.;REEL/FRAME:041735/0662

Effective date: 20160901